Literature DB >> 19787802

Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms.

Giancarlo Troncone1, Marco Volante, Antonino Iaccarino, Pio Zeppa, Immacolata Cozzolino, Umberto Malapelle, Emiliano A Palmieri, Giovanni Conzo, Mauro Papotti, Lucio Palombini.   

Abstract

BACKGROUND: Thyroid fine-needle aspiration (FNA) samples that feature a follicular-patterned, monotonous Hurthle (oncocytic) cell population cannot be diagnosed reliably. The authors of this report recently identified cyclin D3 overexpression on histologic sections of Hurthle cell carcinoma. In this study, they assessed the diagnostic value of cyclin D3 immunohistochemistry added to routine cytology.
METHODS: Fifty-one FNA samples that were suspicious for Hurtle cell neoplasia and that had histologic follow-up (19 malignant cases) were examined. Cyclin D3 expression levels were evaluated in cell block preparations and were compared with levels of the closely related cyclin D1 protein.
RESULTS: Greater than 25% positive cells were used as the cutoff point, as suggested by previous studies. Cyclin D1 and cyclin D3 were highly specific (100% for both) and fairly accurate (75% and 92%, respectively) in distinguishing between benign and malignant oncocytic lesions; the positive predictive value (PPV) for each was 100%. However, both cyclins D1 and D3 had low sensitivity (32% and 79%, respectively) and low negative predictive value (NPV) (71% and 89%, respectively). In contrast, by adopting balanced receiver operating characteristic-derived positive cutoff values, cyclin D1 (>or=6.5%) and cyclin D3 (>or=7.5%) were found to be highly sensitive (100% for both) and accurate (90% and 94%, respectively); and the NPV was 100% for both. In contrast, cyclins D1 and D3 had low specificity (84% and 91%, respectively) and a low PPV (79% and 86%, respectively); however, these values improved in samples that were positive for both cyclins (sensitivity, 100%; specificity, 94%; PPV, 90%; NPV, 100%; and accuracy, 96%).
CONCLUSIONS: Cyclin D3 increased the suspicion of malignancy in indeterminate oncocytic lesions; its diagnostic performance depended on the cutoff point used and was enhanced further when combined with cyclin D1. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787802     DOI: 10.1002/cncy.20050

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  The role of surgery in the current management of differentiated thyroid cancer.

Authors:  Giovanni Conzo; Nicola Avenia; Giuseppe Bellastella; Giancarlo Candela; Annamaria de Bellis; Katherine Esposito; Daniela Pasquali; Andrea Polistena; Luigi Santini; Antonio Agostino Sinisi
Journal:  Endocrine       Date:  2014-04-10       Impact factor: 3.633

2.  Surgical treatment of thyroid follicular neoplasms: results of a retrospective analysis of a large clinical series.

Authors:  Giovanni Conzo; Nicola Avenia; Gian Luca Ansaldo; Piergiorgio Calò; Maurizio De Palma; Chiara Dobrinja; Giovanni Docimo; Claudio Gambardella; Marica Grasso; Celestino Pio Lombardi; Maria Rosa Pelizzo; Angela Pezzolla; Luciano Pezzullo; Micaela Piccoli; Lodovico Rosato; Giuseppe Siciliano; Stefano Spiezia; Ernesto Tartaglia; Francesco Tartaglia; Mario Testini; Giancarlo Troncone; Giuseppe Signoriello
Journal:  Endocrine       Date:  2016-04-13       Impact factor: 3.633

Review 3.  The significance of hurthle cells in thyroid disease.

Authors:  Jennifer Cannon
Journal:  Oncologist       Date:  2011-09-30

4.  The impact of age and oral calcium and vitamin D supplements on postoperative hypocalcemia after total thyroidectomy. A prospective study.

Authors:  Salvatore Tolone; Ruggiero Roberto; Gianmattia del Genio; Luigi Brusciano; Domenico Parmeggiani; Vincenzo Amoroso; Giuseppina Casalino; Ignazio Verde; Alfonso Bosco; Antonio D'Alessandro; Raffaele Pirozzi; Gianluca Rossetti; Paolo Limongelli; Ludovico Docimo
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

5.  CCND1 G870A polymorphism contributes to the risk of esophageal cancer: An updated systematic review and cumulative meta-analysis.

Authors:  Li Wen; Yuan-Yuan Hu; Gong-Li Yang; DE-Xi Liu
Journal:  Biomed Rep       Date:  2014-05-21

6.  CCND1 G870A polymorphism and colorectal cancer risk: An updated meta-analysis.

Authors:  Xiao-Ming Xu; Xiao-Bing Ni; Gong-Li Yang; Zhi-Guo Luo; Yu-Ming Niu; Ming Shen
Journal:  Mol Clin Oncol       Date:  2016-04-04

7.  Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.

Authors:  Andrii Dinets; Mykola Hulchiy; Anastasios Sofiadis; Mehran Ghaderi; Anders Höög; Catharina Larsson; Jan Zedenius
Journal:  Eur J Endocrinol       Date:  2012-03-28       Impact factor: 6.664

8.  Effect of the CCND1 A870G polymorphism on prostate cancer risk: a meta-analysis of 3,820 cases and 3,825 controls.

Authors:  Min Zheng; Lijun Wan; Xiang He; Xiaolong Qi; Feng Liu; Da-Hong Zhang
Journal:  World J Surg Oncol       Date:  2015-02-15       Impact factor: 2.754

9.  Leiomyosarcoma of the thyroid gland: A case report and literature review.

Authors:  Giovanni Conzo; Giancarlo Candela; Ernesto Tartaglia; Claudio Gambardella; Claudio Mauriello; Guido Pettinato; Giuseppe Bellastella; Kathrine Esposito; Luigi Santini
Journal:  Oncol Lett       Date:  2014-02-04       Impact factor: 2.967

10.  Predictive value of nodal metastases on local recurrence in the management of differentiated thyroid cancer. Retrospective clinical study.

Authors:  Giovanni Conzo; Giovanni Docimo; Daniela Pasquali; Claudio Mauriello; Claudio Gambardella; Daniela Esposito; Ernesto Tartaglia; Cristina Della Pietra; Salvatore Napolitano; Antonia Rizzuto; Luigi Santini
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.